Marc Stapley joined Veracyte in 2021 as Chief Executive Officer and a member of the company’s board of directors. Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global enterprises.
Prior to Veracyte, he served as Chairman and Chief Executive Officer of Helix, a leading population genomics company, from 2019 to 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.
Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina from 2012 to 2019, including as Chief Financial Officer, Chief Administrative Officer and Executive Vice President, where he led many functions including G&A, corporate strategy, business development, population genomics, and government affairs.
Prior to Illumina, Mr. Stapley was Senior Vice President, Finance, at Pfizer Inc. and before that, he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC).
He currently serves as a member of the board of directors of Helix and Glaukos. Mr. Stapley holds a B.Sc. (Honors) in Mathematics from the University of Reading (England).
What makes working at Veracyte so meaningful is knowing that the science we advance directly impacts people’s lives. We’re not just developing tests; we’re creating a novel platform that helps clinicians give patients clearer answers and more personalized treatment plans when they need them most. It’s incredibly rewarding to be a part of a team that’s focused on bringing the right pieces together to make a real difference in cancer care.”
Marc Stapley | Chief Executive Officer